60
Participants
Start Date
April 10, 2025
Primary Completion Date
March 31, 2028
Study Completion Date
March 31, 2029
arfolitixorin (ARFOX + bevacizumab)
Every 14 days during treatment phase, Bevacizumab will be administered as an i.v. infusion of 5 mg/kg, Oxaliplatin will be administered as an 85 mg/m2 i.v. infusion, 5-FU will be administered as a 400 mg/m2 i.v. bolus + a 2,400 mg/m2 i.v. infusion and Arfolitixorin will be administred as an i.v. infusion.
RECRUITING
Charité - Universitaetsmedizin Berlin, Berlin
Lead Sponsor
Charite University, Berlin, Germany
OTHER
Isofol Medical AB
INDUSTRY